Amgen Inc. $AMGN Shares Purchased by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 9.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,314 shares of the medical research company’s stock after purchasing an additional 1,012 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Amgen were worth $3,438,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Bell & Brown Wealth Advisors LLC raised its stake in shares of Amgen by 2.2% during the second quarter. Bell & Brown Wealth Advisors LLC now owns 11,134 shares of the medical research company’s stock worth $3,120,000 after purchasing an additional 237 shares during the last quarter. Foster & Motley Inc. raised its position in Amgen by 1.0% in the second quarter. Foster & Motley Inc. now owns 34,459 shares of the medical research company’s stock worth $9,621,000 after acquiring an additional 353 shares in the last quarter. Huntleigh Advisors Inc. raised its position in Amgen by 3.9% in the second quarter. Huntleigh Advisors Inc. now owns 9,910 shares of the medical research company’s stock worth $2,767,000 after acquiring an additional 368 shares in the last quarter. Kanawha Capital Management LLC raised its position in Amgen by 18.9% in the second quarter. Kanawha Capital Management LLC now owns 1,170 shares of the medical research company’s stock worth $327,000 after acquiring an additional 186 shares in the last quarter. Finally, Nicholson Wealth Management Group LLC raised its position in Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after acquiring an additional 35 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

NASDAQ:AMGN opened at $298.81 on Friday. The firm has a market cap of $160.87 billion, a price-to-earnings ratio of 24.43, a price-to-earnings-growth ratio of 2.61 and a beta of 0.49. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The company’s 50-day moving average is $287.14 and its two-hundred day moving average is $287.27. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Friday, August 22nd. Amgen’s dividend payout ratio is 77.84%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Morgan Stanley raised their price target on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Weiss Ratings upgraded Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Piper Sandler raised their price target on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. UBS Group dropped their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research report on Wednesday, August 6th. Finally, Bank of America raised their price target on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. Seven investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $305.50.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.